List of Tables
Table 1. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Treatment of Extensive-stage Small Cell Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Treatment of Extensive-stage Small Cell Lung Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Treatment of Extensive-stage Small Cell Lung Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Treatment of Extensive-stage Small Cell Lung Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of Treatment of Extensive-stage Small Cell Lung Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Treatment of Extensive-stage Small Cell Lung Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Treatment of Extensive-stage Small Cell Lung Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales by Region (K Units), 2021–2026
Table 18. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Region (2021–2026)
Table 19. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales by Region (K Units), 2027–2032
Table 20. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Region (2027–2032)
Table 21. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 27. North America Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 28. North America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Type (2021–2026)
Table 53. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Type (2027–2032)
Table 54. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Application (2021–2026)
Table 63. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Application (2027–2032)
Table 64. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. G1 Therapeutics Company Information
Table 71. G1 Therapeutics Description and Business Overview
Table 72. G1 Therapeutics Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. G1 Therapeutics Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 74. G1 Therapeutics Recent Developments/Updates
Table 75. Simcere Pharmaceutical Group Company Information
Table 76. Simcere Pharmaceutical Group Description and Business Overview
Table 77. Simcere Pharmaceutical Group Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Simcere Pharmaceutical Group Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 79. Simcere Pharmaceutical Group Recent Developments/Updates
Table 80. Junshi Biosciences Company Information
Table 81. Junshi Biosciences Description and Business Overview
Table 82. Junshi Biosciences Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Junshi Biosciences Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 84. Junshi Biosciences Recent Developments/Updates
Table 85. Henan Biopharma Company Information
Table 86. Henan Biopharma Description and Business Overview
Table 87. Henan Biopharma Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Henan Biopharma Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 89. Henan Biopharma Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AstraZeneca Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Roche Company Information
Table 96. Roche Description and Business Overview
Table 97. Roche Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Roche Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 99. Roche Recent Developments/Updates
Table 100. Bristol-Myers Squibb Company Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Bristol-Myers Squibb Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 104. Bristol-Myers Squibb Recent Developments/Updates
Table 105. Merck Company Information
Table 106. Merck Description and Business Overview
Table 107. Merck Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Merck Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 109. Merck Recent Developments/Updates
Table 110. Pfizer Company Information
Table 111. Pfizer Description and Business Overview
Table 112. Pfizer Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Pfizer Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 114. Pfizer Recent Developments/Updates
Table 115. Innovent Biologics Company Information
Table 116. Innovent Biologics Description and Business Overview
Table 117. Innovent Biologics Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Innovent Biologics Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 119. Innovent Biologics Recent Developments/Updates
Table 120. Hengrui Medicine Company Information
Table 121. Hengrui Medicine Description and Business Overview
Table 122. Hengrui Medicine Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Hengrui Medicine Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 124. Hengrui Medicine Recent Developments/Updates
Table 125. BeiGene Company Information
Table 126. BeiGene Description and Business Overview
Table 127. BeiGene Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. BeiGene Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 129. BeiGene Recent Developments/Updates
Table 130. Zhengda Tianqing Company Company Information
Table 131. Zhengda Tianqing Company Description and Business Overview
Table 132. Zhengda Tianqing Company Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Zhengda Tianqing Company Treatment of Extensive-stage Small Cell Lung Cancer Product
Table 134. Zhengda Tianqing Company Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Treatment of Extensive-stage Small Cell Lung Cancer Distributors List
Table 138. Treatment of Extensive-stage Small Cell Lung Cancer Customers List
Table 139. Treatment of Extensive-stage Small Cell Lung Cancer Market Trends
Table 140. Treatment of Extensive-stage Small Cell Lung Cancer Market Drivers
Table 141. Treatment of Extensive-stage Small Cell Lung Cancer Market Challenges
Table 142. Treatment of Extensive-stage Small Cell Lung Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Treatment of Extensive-stage Small Cell Lung Cancer
Figure 2. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Share by Type: 2025 & 2032
Figure 4. Chemotherapy Product Picture
Figure 5. Immunotherapy Product Picture
Figure 6. Radiotherapy Product Picture
Figure 7. Other Product Picture
Figure 8. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Size (US$ Million), 2021–2032
Figure 14. Global Treatment of Extensive-stage Small Cell Lung Cancer Sales (K Units), 2021–2032
Figure 15. Global Treatment of Extensive-stage Small Cell Lung Cancer Average Price (US$/Unit), 2021–2032
Figure 16. Treatment of Extensive-stage Small Cell Lung Cancer Report Years Considered
Figure 17. Treatment of Extensive-stage Small Cell Lung Cancer Sales Share by Manufacturers in 2025
Figure 18. Global Treatment of Extensive-stage Small Cell Lung Cancer Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Treatment of Extensive-stage Small Cell Lung Cancer Players: Market Share by Revenue in Treatment of Extensive-stage Small Cell Lung Cancer in 2025
Figure 20. Treatment of Extensive-stage Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Treatment of Extensive-stage Small Cell Lung Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 23. North America Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 24. United States Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 27. Europe Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 28. Germany Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Region (2021–2032)
Figure 35. China Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 43. Latin America Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Treatment of Extensive-stage Small Cell Lung Cancer Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Treatment of Extensive-stage Small Cell Lung Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Treatment of Extensive-stage Small Cell Lung Cancer by Type (2021–2032)
Figure 54. Global Revenue Market Share of Treatment of Extensive-stage Small Cell Lung Cancer by Type (2021–2032)
Figure 55. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of Treatment of Extensive-stage Small Cell Lung Cancer by Application (2021–2032)
Figure 57. Global Revenue Market Share of Treatment of Extensive-stage Small Cell Lung Cancer by Application (2021–2032)
Figure 58. Global Treatment of Extensive-stage Small Cell Lung Cancer Price (US$/Unit) by Application (2021–2032)
Figure 59. Treatment of Extensive-stage Small Cell Lung Cancer Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
